LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
LIFECORE BIOMEDICAL, INC. DE
Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.10 (−1.54%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
LIFECORE BIOMEDICAL, INC. DE grew revenue 0.5% to $128.87M over the twelve months to May 25, 2025. Free cash flow was -$13.62M.
Revenue
$128.87M
+0.5% vs. a year earlier
Operating income
-$17.25M
TTM Q4 2025
Free cash flow
-$13.62M
TTM Q4 2025
EPS, diluted
-$1.27
-484.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $128.87M
- Net income
- -$38.72M
- EPS, diluted
- -$1.27
- Free cash flow
- -$13.62M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
$128.87M+0.5% YoY
Gross profit
$40.30M-3.7% YoY
Operating income
-$17.25M
Net income
-$38.72M-422.3% YoY
EPS, diluted
-$1.27-484.8% YoY
Free cash flow
-$13.62M
Reported period